1
|
Ogunro OB. An updated and comprehensive review of the health benefits and pharmacological activities of hesperidin. Biochem Biophys Res Commun 2025; 772:151974. [PMID: 40414011 DOI: 10.1016/j.bbrc.2025.151974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2025] [Revised: 05/06/2025] [Accepted: 05/07/2025] [Indexed: 05/27/2025]
Abstract
OBJECTIVES This review aims to comprehensively assess the health benefits and pharmacological activities of hesperidin, a flavonoid commonly found in citrus fruits. It consolidates recent research findings to provide insights into hesperidin's diverse health-promoting effects. KEY FINDINGS Hesperidin has gained significant attention recently for its notable pharmacological activities and potential health benefits. Studies reveal its antioxidant properties, protecting cells from oxidative damage, and its anti-inflammatory effects, inhibiting pro-inflammatory cytokines and enzymes. Also, hesperidin shows promise in cardiovascular health by reducing blood pressure and cholesterol levels and enhancing endothelial function. It also exhibits anticancer potential by hindering cell proliferation, inducing apoptosis, and suppressing tumour growth. Moreover, hesperidin demonstrates neuroprotective effects, potentially mitigating neuroinflammation and oxidative stress associated with neurodegenerative diseases. Furthermore, it displays beneficial effects in metabolic disorders such as diabetes, obesity, and fatty liver disease by influencing glucose metabolism, lipid profile, and insulin sensitivity. SUMMARY Hesperidin exhibits a wide range of health benefits and pharmacological activities, making it a promising candidate for therapeutic interventions in various diseases. Its antioxidant, anti-inflammatory, cardiovascular, anticancer, neuroprotective, and metabolic effects underscore its potential as a valuable natural compound for promoting health and preventing chronic diseases.
Collapse
Affiliation(s)
- Olalekan Bukunmi Ogunro
- Drug Discovery, Toxicology, and Pharmacology Research Laboratory, Department of Biological Sciences, KolaDaisi University, Ibadan, Nigeria.
| |
Collapse
|
2
|
Munir M, Forentin AM, Febrian MB, Fakih TM, Utomo RY, Aries A, Lestari W, Meiyanto E, Muchtaridi M, Septisetyani EP, Astirin OP, Syaifudin M. Radiosynthesis of [ 131I]I-Hesperidin: Optimization, physicochemical profiling, and computational insights for targeted radiopharmaceuticals. Appl Radiat Isot 2025; 225:111977. [PMID: 40516338 DOI: 10.1016/j.apradiso.2025.111977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2025] [Revised: 05/24/2025] [Accepted: 06/04/2025] [Indexed: 06/16/2025]
Abstract
Hesperidin, a citrus flavonoid, has been investigated for its potential health benefits, including anticancer. However, the study of hesperidin as a theranostic agent and its cancer cellular uptake is still lacking. Therefore, in this research, we developed radiolabeling methods of hesperidin with Iodine-131 (131I) for radiotracing and investigating its potential theranostic application. Here, we showed that the radiochemical purity of [131I]I-hesperidin prepared with chloramine-T in methanol or DMSO, iodogen, and iodobeads as a catalyst were 97.75, 79.08, 78.13, and 49.91 %, respectively. The LogP and plasma protein-binding after 24 h of [131I]I-hesperidin prepared by chloramine-T in methanol were 0.54 ± 0.02 and 51.01 %, respectively. It was also stable in PBS for up to two days (RCP>90 %). The cellular uptake assay demonstrated the high and rapid uptake of [131I]I- hesperidin in A549 cells (92.03 % in 30 min), relatively low uptake in MCF-7 (21.30 % in 1 h), and deficient uptake in MDA-MB-231 (3.64 %). Interaction and binding energies of [131I]I-hesperidin-b toward EGFR, HER2, ERα, and ERβ, were -169.910; -131.574; -152.623, and -184.844 kJ/mol, respectively. Considering that the cellular uptake was the highest in A549 cells among the tested cells, the cellular uptake may be related to both EGFR and HER2 receptors. In addition, the interaction and binding energy of [131I]I-hesperidin-b toward AKT1 was -150.939 kJ/mol, indicating the potential [131I]I-hesperidin-b intervention in EGFR/HER2 signaling. Our data suggest that [131I]I-hesperidin-b is a potential radiopharmaceutical, especially for lung cancers with EGFR and HER2 expression. However, further studies are still needed to evaluate the uptake mechanism of [131I]I-hesperidin at the molecular level. Hopefully, [131I]I-hesperidin will provide an opportunity to investigate the biodistribution, pharmacokinetics, and its potential as a targeted therapeutic-diagnostic agent supported with beta decay for cancer cell eradication.
Collapse
Affiliation(s)
- Miftakul Munir
- Research Center for Radioisotope, Radiopharmaceutical and Biodosimetry Technology, Research Organization for Nuclear Energy, National Research and Innovation Agency (BRIN), Building 71, Kawasan Puspiptek, Setu, Tangerang Selatan, Banten, 15310, Indonesia; School of Biomedical Sciences, Faculty of Health Medicine and Behavioural Sciences, the University of Queensland, Australia
| | - Alfian Mahardika Forentin
- Research Center for Radioisotope, Radiopharmaceutical and Biodosimetry Technology, Research Organization for Nuclear Energy, National Research and Innovation Agency (BRIN), Building 71, Kawasan Puspiptek, Setu, Tangerang Selatan, Banten, 15310, Indonesia
| | - Muhammad Basit Febrian
- Research Center for Radioisotope, Radiopharmaceutical and Biodosimetry Technology, Research Organization for Nuclear Energy, National Research and Innovation Agency (BRIN), Building 71, Kawasan Puspiptek, Setu, Tangerang Selatan, Banten, 15310, Indonesia
| | - Taufik Muhammad Fakih
- Department of Pharmaceutical Analysis and Medicinal Chemistry, Universitas Padjadjaran, Jl. Raya Bandung Sumedang KM 21, Sumedang, 45363, Indonesia; Department of Pharmacy, Universitas Islam Bandung, Jl. Ranggagading, Bandung, 40116, Indonesia
| | - Rohmad Yudi Utomo
- Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara, Yogyakarta, 55281, Indonesia; Laboratory of Medicinal Chemistry, Department of Pharmaceutical Chemistry, Universitas Gadjah Mada, Sekip Utara, Yogyakarta, 55281, Indonesia
| | - Arni Aries
- Research Center for Radioisotope, Radiopharmaceutical and Biodosimetry Technology, Research Organization for Nuclear Energy, National Research and Innovation Agency (BRIN), Building 71, Kawasan Puspiptek, Setu, Tangerang Selatan, Banten, 15310, Indonesia; Research Collaboration Center for Theranostic Radiopharmaceuticals, Jl Ir. Soekarno KM 21, Jatinangor, 45363, Indonesia
| | - Wening Lestari
- Research Center for Radioisotope, Radiopharmaceutical and Biodosimetry Technology, Research Organization for Nuclear Energy, National Research and Innovation Agency (BRIN), Building 71, Kawasan Puspiptek, Setu, Tangerang Selatan, Banten, 15310, Indonesia
| | - Edy Meiyanto
- Laboratory of Medicinal Chemistry, Department of Pharmaceutical Chemistry, Universitas Gadjah Mada, Sekip Utara, Yogyakarta, 55281, Indonesia; Laboratory of Macromolecular Engineering, Department of Pharmaceutical Chemistry, Universitas Gadjah Mada, Sekip Utara, Yogyakarta, 55281, Indonesia
| | - Muchtaridi Muchtaridi
- Department of Pharmaceutical Analysis and Medicinal Chemistry, Universitas Padjadjaran, Jl. Raya Bandung Sumedang KM 21, Sumedang, 45363, Indonesia; Research Collaboration Center for Theranostic Radiopharmaceuticals, Jl Ir. Soekarno KM 21, Jatinangor, 45363, Indonesia
| | - Endah Puji Septisetyani
- Research Center for Genetic Engineering, National Research and Innovation Agency, KST Soekarno, Jl. Raya Bogor KM 46, Cibinong, Bogor, 16911, Indonesia
| | - Okid Parama Astirin
- Department of Biology, Faculty of Mathematics and Natural Science, Universitas Sebelas Maret, Surakarta, 57126, Indonesia
| | - Mukh Syaifudin
- Research Center for Radioisotope, Radiopharmaceutical and Biodosimetry Technology, Research Organization for Nuclear Energy, National Research and Innovation Agency (BRIN), Building 71, Kawasan Puspiptek, Setu, Tangerang Selatan, Banten, 15310, Indonesia; Research Collaboration Center for Theranostic Radiopharmaceuticals, Jl Ir. Soekarno KM 21, Jatinangor, 45363, Indonesia.
| |
Collapse
|
3
|
Félix J, Díaz-Del Cerro E, Baca A, López-Ballesteros A, Gómez-Sánchez MJ, De la Fuente M. Human Supplementation with AM3, Spermidine, and Hesperidin Enhances Immune Function, Decreases Biological Age, and Improves Oxidative-Inflammatory State: A Randomized Controlled Trial. Antioxidants (Basel) 2024; 13:1391. [PMID: 39594533 PMCID: PMC11591374 DOI: 10.3390/antiox13111391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2024] [Revised: 11/08/2024] [Accepted: 11/13/2024] [Indexed: 11/28/2024] Open
Abstract
The positive effect of AM3, spermidine, and hesperidin, which have antioxidant and anti-inflammatory properties, on immunity is known, but their effect on the rate of aging, known as biological age (BA), is unclear. This work aims to test if the intake of a blend of AM3 (150 mg), spermidine (0.6 mg), and hesperidin (50 mg) for 2 months could decrease BA and improve immunity, redox, and inflammatory states. For this, 41 participants (30-63 years) were randomly divided into placebo and supplement groups. The supplement group took two capsules daily with AM3, spermidine, and hesperidin for two months, while the placebo group took capsules containing only calcium phosphate and talcum powder. Before and after the treatment, peripheral blood was collected. Immune function was assessed in leukocytes, redox state in whole-blood cells, erythrocytes, and plasma, and cytokine concentration in both mononuclear cell cultures and plasma. Finally, the Immunity Clock model was applied to determine BA. The results show that the intake of this blend improves the immune functions that constitute the Immunity Clock, decreasing BA by 11 years and reducing the oxidative-inflammatory state of the participants. Therefore, this supplement can be proposed as a strategy to rejuvenate BA and achieve healthy aging.
Collapse
Affiliation(s)
- Judith Félix
- Department of Genetics, Physiology and Microbiology (Animal Physiology Unit), Faculty of Biological Sciences, Complutense University of Madrid, 28040 Madrid, Spain; (E.D.-D.C.); (A.B.)
- Institute of Investigation Hospital 12 Octubre (Imas12), 28041 Madrid, Spain
| | - Estefanía Díaz-Del Cerro
- Department of Genetics, Physiology and Microbiology (Animal Physiology Unit), Faculty of Biological Sciences, Complutense University of Madrid, 28040 Madrid, Spain; (E.D.-D.C.); (A.B.)
- Institute of Investigation Hospital 12 Octubre (Imas12), 28041 Madrid, Spain
| | - Adriana Baca
- Department of Genetics, Physiology and Microbiology (Animal Physiology Unit), Faculty of Biological Sciences, Complutense University of Madrid, 28040 Madrid, Spain; (E.D.-D.C.); (A.B.)
| | | | | | - Mónica De la Fuente
- Department of Genetics, Physiology and Microbiology (Animal Physiology Unit), Faculty of Biological Sciences, Complutense University of Madrid, 28040 Madrid, Spain; (E.D.-D.C.); (A.B.)
- Institute of Investigation Hospital 12 Octubre (Imas12), 28041 Madrid, Spain
| |
Collapse
|